Emmaus Life Scie Stock Price, News & Analysis

Emmaus Life Sciences (OTCQX: EMMA) celebrated Dr. Yutaka Niihara's recognition by India's Minister of State, Arun Halder, for his work on Endari® at an event in Mumbai on December 16, 2022. Sickle cell disease (SCD) affects over 20 million people in India, particularly among tribal communities. Endari® is approved in the U.S. and other regions but not yet in India. Emmaus aims to explore market entry opportunities in India to provide treatments for SCD patients. Forward-looking statements regarding market access are included in the PR.

Emmaus Life Sciences, Inc. (OTCQX: EMMA) has secured marketing authorization for its sickle cell disease treatment, Endari®, from the Kuwaiti Ministry of Health. This approval marks Kuwait as the third Gulf Cooperation Council (GCC) country to endorse Endari®, following similar approvals in the United Arab Emirates and Qatar earlier in the year. Dr. Yutaka Niihara stated that this progress is crucial for expanding Endari's availability to sickle cell patients in the region, with expectations of positive operating cash flows in 2023.

Emmaus Life Sciences, Inc. (OTCQX: EMMA) reported a 15% increase in net revenue to $4.9 million for Q3 2022, despite a decrease compared to $5.8 million in Q3 2021. The company faced challenges with production delays but remains optimistic for Q4 sales. Loss from operations decreased to $0.7 million from $1.4 million in Q2 2022. However, total operating expenses fell to $5.1 million from $5.4 million year-over-year, and liquidity issues persist with cash reserves at $1.2 million. Emmaus continues to explore refinancing options to address current liabilities.

Emmaus Life Sciences (OTCQX: EMMA) announced a partnership with Kier (Junior) Spates from the Steve Harvey Morning Show to raise awareness about sickle cell disease (SCD) and promote Endari, its L-glutamine oral powder treatment. This collaboration aims to destigmatize SCD and inform millions of listeners about available treatment options as many SCD patients hesitate to seek help. Endari has been FDA-approved since July 2017 and is indicated for adults and children over five, yet faced challenges in reaching underrepresented communities. The initiative seeks to address healthcare access disparities.

Emmaus Life Sciences, Inc. (OTCQX: EMMA) announced its Q2 2022 financial results, reporting net revenues of $4.3 million, down from $6.5 million in Q2 2021. The company experienced a 33% increase in Q2 revenues from Q1 2022, driven by sales of Endari in the U.A.E. Net loss for Q2 2022 totaled $8.9 million or $0.18 per share, compared to a net income of $2.5 million in Q2 2021. Operating expenses decreased slightly to $5.3 million. The company reported cash and cash equivalents of $1.0 million as of June 30, 2022, and is exploring debt restructuring.

Emmaus Life Sciences, Inc. (OTCQX: EMMA) has engaged Acorn Management Partners to enhance investor awareness among financial professionals. This collaboration aims to broaden Emmaus's investor base in the U.S. and the Middle East North Africa region. Emmaus, a leader in sickle cell disease treatment, markets the FDA-approved Endari® (L-glutamine oral powder). Acorn’s expertise in investor relations and their strategic outreach program will support Emmaus's goal to deliver its innovative therapies effectively.

Emmaus Life Sciences, Inc. (OTCQX: EMMA), based in Torrance, California, will participate in two investor conferences in May 2022. The first event, the Q2 Investor Summit, will occur on May 3-4, where CEO Yutaka Niihara will present at 3:30 p.m. ET. The H.C Wainwright Global Investment Conference is scheduled for May 23-26, with an on-demand presentation available from May 24, 2022, at 7:00 a.m. ET. One-on-one meetings can be arranged with management during both conferences.

Emmaus Life Sciences (OTQXC: EMMA) has launched a full-service telehealth solution to enhance access to its product Endari®, an L-glutamine oral powder for sickle cell disease treatment. This initiative, in partnership with Asembia LLC, US Bioservices Corporation, and UpScript IP Holdings, enables patients to receive prescriptions and home delivery, improving patient experience and adherence rates. With the telehealth market experiencing significant growth, Emmaus aims to reach new patients and generate revenue through this innovative service.